共 50 条
Then and now: The progress in hepatitis B treatment over the past 20 years
被引:0
|作者:
Dina Halegoua-De Marzio
[1
]
Hie-Won Hann
[1
,2
]
机构:
[1] Division of Gastroenterology and Hepatology,Department of Medicine,Thomas Jefferson University Hospital,Philadelphia,PA 19107,United States
[2] Liver Disease Prevention Center,Division of Gastroenterology and Hepatology,Thomas Jefferson University Hospital,Philadelphia,PA 19107,United States
关键词:
Chronic hepatitis B;
Treatment of hepatitis B;
Hepatocellular carcinoma;
Nucleoside analogues;
Nucleotide analogues;
D O I:
暂无
中图分类号:
R512.62 [];
学科分类号:
100401 ;
摘要:
The ultimate goals of treating chronic hepatitis B(CHB)is prevention of hepatocellular carcinoma(HCC)and hepatic decompensation.Since the advent of effective antiviral drugs that appeared during the past two decades,considerable advances have been made not only in controlling hepatitis B virus(HBV)infection,but also in preventing and reducing the incidence of liver cirrhosis and HCC.Furthermore,several recent studies have suggested the possibility of reducing the incidence of recurrent or new HCC in patients even after they have developed HCC.Currently,six medications are available for HBV treatment including,interferon and five nucleoside/nucleotide analogues.In this review,we will examine the antiviral drugs and the progresses that have been made with antiviral treatments in the field of CHB.
引用
收藏
页码:401 / 413
页数:13
相关论文